Sutro Biopharma (STRO) Current Leases (2021 - 2026)

Sutro Biopharma has reported Current Leases for 5 years, with the latest figure at $7.8 million in Q4 2025.

• Quarterly Current Leases rose 4.05% year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (up 4.05% YoY) and the FY2025 annual result came in at $7.8 million, up 4.05% from the prior year.
• Current Leases retreated to $7.8 million in Q4 2025 per STRO's latest filing, from $8.0 million in the prior quarter.
• Over five years, Current Leases peaked at $8.1 million in Q2 2025 and troughed at $1.0 million in Q4 2021.
• A 5-year average of $5.3 million and a median of $6.3 million in 2023 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2025: Current Leases jumped 429.82% in 2023, then gained 4.05% in 2025.
• Over 5 years, Current Leases stood at $1.0 million in 2021, then jumped by 342.14% to $4.6 million in 2022, then jumped by 40.02% to $6.4 million in 2023, then increased by 16.51% to $7.5 million in 2024, then grew by 4.05% to $7.8 million in 2025.
• According to Business Quant data, Current Leases over the past three periods registered $7.8 million, $8.0 million, and $8.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.